BDF Gestion Sells 3,221 Shares of Johnson & Johnson $JNJ

Key Points

• BDF Gestion has reduced its holdings in Johnson & Johnson by 9.8%, now owning 29,556 shares valued at approximately $4.5 million.
• Johnson & Johnson reported earnings of $2.77 per share for the last quarter, surpassing consensus estimates and achieving revenue of $23.74 billion.
• The company announced a quarterly dividend of $1.30 per share, representing an annual yield of 3.0% and a payout ratio of 55.61%.

BDF Gestion lessened its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 9.8% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 29,556 shares of the company's stock after selling 3,221 shares during the period. BDF Gestion's holdings in Johnson & Johnson were worth $4,515,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Elios Financial Group Inc. raised its stake in Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after buying an additional 66 shares during the last quarter. Atlantic Family Wealth LLC increased its stake in Johnson & Johnson by 4.4% in the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after purchasing an additional 67 shares in the last quarter. MBA Advisors LLC increased its stake in Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after purchasing an additional 68 shares in the last quarter. Sovereign Financial Group Inc. increased its stake in Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after purchasing an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc increased its stake in Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after purchasing an additional 69 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on JNJ shares. The Goldman Sachs Group lifted their price objective on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a "buy" rating in a report on Friday. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Royal Bank Of Canada lifted their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Guggenheim upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $167.00 to $206.00 in a report on Tuesday. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a report on Tuesday, September 16th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $181.40.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock traded up $2.19 during trading on Tuesday, reaching $176.40. 3,238,731 shares of the company's stock traded hands, compared to its average volume of 8,915,940. The company has a market capitalization of $424.82 billion, a P/E ratio of 18.87, a PEG ratio of 2.24 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm's 50-day moving average is $173.14 and its 200 day moving average is $161.69. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.